ES2536460T3 - Formulación de acción prolongada y liberación controlada que contiene un agonista de receptores de dopamina y método de preparación de la misma - Google Patents

Formulación de acción prolongada y liberación controlada que contiene un agonista de receptores de dopamina y método de preparación de la misma Download PDF

Info

Publication number
ES2536460T3
ES2536460T3 ES05792179.3T ES05792179T ES2536460T3 ES 2536460 T3 ES2536460 T3 ES 2536460T3 ES 05792179 T ES05792179 T ES 05792179T ES 2536460 T3 ES2536460 T3 ES 2536460T3
Authority
ES
Spain
Prior art keywords
preparation
controlled release
day
acting
long
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05792179.3T
Other languages
English (en)
Spanish (es)
Inventor
Luping Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shandong Luye Pharmaceutical Co Ltd
Original Assignee
Shandong Luye Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shandong Luye Pharmaceutical Co Ltd filed Critical Shandong Luye Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2536460T3 publication Critical patent/ES2536460T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES05792179.3T 2004-09-21 2005-09-21 Formulación de acción prolongada y liberación controlada que contiene un agonista de receptores de dopamina y método de preparación de la misma Expired - Lifetime ES2536460T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN200410077961 2004-09-21
CN200410077961 2004-09-21
PCT/CN2005/001521 WO2006032202A1 (fr) 2004-09-21 2005-09-21 Formulation à libération lente et prolongée contenant un agoniste du récepteur de la dopamine et son procédé de préparation

Publications (1)

Publication Number Publication Date
ES2536460T3 true ES2536460T3 (es) 2015-05-25

Family

ID=36089849

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05792179.3T Expired - Lifetime ES2536460T3 (es) 2004-09-21 2005-09-21 Formulación de acción prolongada y liberación controlada que contiene un agonista de receptores de dopamina y método de preparación de la misma

Country Status (9)

Country Link
US (2) US8691277B2 (https=)
EP (1) EP1797871B1 (https=)
JP (1) JP5081622B2 (https=)
KR (1) KR20070059161A (https=)
AU (1) AU2005287743B2 (https=)
CA (1) CA2581143C (https=)
ES (1) ES2536460T3 (https=)
PL (1) PL1797871T3 (https=)
WO (1) WO2006032202A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7435738B2 (en) 2003-08-18 2008-10-14 Solvay Pharmaceuticals, Inc. Stable crystalline form of bifeprunox mesylate (7-[4-([1,1′-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate)
US7405216B2 (en) 2004-08-18 2008-07-29 Solvay Pharmaceuticals, B.V. Stable crystalline form of bifeprunox mesylate (7-[4-([1,1′-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate)
US7423040B2 (en) 2005-02-18 2008-09-09 Irene Eijgendaal Stable crystalline form of bifeprunox mesylate, dosage forms thereof and methods for using same
US7964604B2 (en) 2005-02-18 2011-06-21 Solvay Pharmaceuticals B.V. Bifeprunox mesylate maintenance dose compositions and methods for using the same
ES2402376T3 (es) * 2006-04-06 2013-05-03 Nupathe Inc. Implantes para el tratamiento de estados asociados con dopamina
US8106056B2 (en) 2006-06-16 2012-01-31 Solvay Pharmaceuticals B.V. Combination preparations comprising bifeprunox and a dopamine agonist
US7786126B2 (en) 2006-06-16 2010-08-31 Solvay Pharmaceuticals B.V. Combination preparations comprising SLV308 and a dopamine agonist
JP2009539941A (ja) * 2006-06-16 2009-11-19 ソルベイ・フアーマシユーチカルズ・ベー・ブイ Ｓｌｖ３０８およびｌ−ｄｏｐａを含んでなる組み合わせ製剤
TWI392670B (zh) * 2006-06-22 2013-04-11 Ucb Pharma Gmbh 經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途
WO2008009665A1 (en) * 2006-07-19 2008-01-24 Boehringer Ingelheim International Gmbh Treatment of pain
EP2291178A4 (en) * 2008-06-09 2013-07-24 Supernus Pharmaceuticals Inc PRAMIPEXOL FORMULATIONS WITH CONTROLLED RELEASE
EP2452677A1 (en) 2008-09-29 2012-05-16 Wockhardt Limited Extended release dosage form of ropinirole
FR2936710B1 (fr) * 2008-10-07 2011-01-07 Ceva Sante Animale Composition veterinaire antiprolactinique destinee aux ruminants
AU2010266285A1 (en) * 2009-07-02 2012-02-09 Supernus Pharmaceuticals, Inc. A method of treatment of a neurological disorder
WO2011012723A1 (en) 2009-07-31 2011-02-03 Ascendis Pharma As Injectable sustained release compositions comprising a pramipexole prodrug
US20120191039A1 (en) 2009-07-31 2012-07-26 Ascendis Pharma A/S Carrier linked pramipexole prodrugs
DE102010014113A1 (de) * 2010-04-07 2011-10-13 Acino Ag Freisetzungsverfahren für Implantate
RU2589700C2 (ru) * 2010-11-25 2016-07-10 Шан Донг Люие Фармацеутикал Ко., Лтд Композиции ротиготина, его производных, или фармацевтически приемлемых солей ротиготина или их производных
WO2012074988A1 (en) * 2010-12-02 2012-06-07 Ratiopharm Gmbh Rotigotine ionic liquid
US9956201B2 (en) 2014-07-21 2018-05-01 Spriaso Llc Compositions comprising bioreversible derivatives of hydroxy N-substituted-2-aminotetralins, and related dosage forms
WO2018096560A1 (en) 2016-11-23 2018-05-31 Cipla Limited Long acting depot formulation for the continuous dopaminergic stimulation
US20190374534A1 (en) 2018-06-08 2019-12-12 Boehringer Ingelheim Vetmedica Gmbh Liquid pharmaceutical compositions comprising pergolide
KR102212722B1 (ko) * 2019-12-23 2021-02-08 환인제약 주식회사 로피니롤을 포함하는 마이크로스피어 및 이를 함유하는 주사제 조성물
WO2025243901A1 (ja) * 2024-05-21 2025-11-27 株式会社 SENTAN Pharma 注射製剤

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166800A (en) * 1977-08-25 1979-09-04 Sandoz, Inc. Processes for preparation of microspheres
JP2651320B2 (ja) * 1992-07-16 1997-09-10 田辺製薬株式会社 徐放性マイクロスフェア製剤の製造方法
KR20000015944A (ko) * 1996-05-24 2000-03-15 팜 윌리암 엔. 신체 통로의 질병을 치료 또는 예방하기 위한조성물 및 방법
JPH10167968A (ja) * 1996-10-09 1998-06-23 Takeda Chem Ind Ltd マイクロパーティクルの製造法
CA2267930A1 (en) 1996-10-09 1998-04-16 Nobuyuki Takechi A method for producing a microparticle
ATE203157T1 (de) * 1996-12-20 2001-08-15 Alza Corp Injizierbare depotgelzubereitung und herstellungsverfahren
JP3663271B2 (ja) * 1997-01-24 2005-06-22 シュバルツ ファルマ アクチェンゲゼルシャフト 新規の分枝鎖エステル及びその製法
AU752225B2 (en) * 1998-07-17 2002-09-12 Pacira Pharmaceuticals, Inc. Biodegradable compositions for the controlled release of encapsulated substances
DK1140026T3 (da) * 1998-12-16 2006-01-02 Aventis Pharma Inc Serotoninreceptorantagonist indkapslet i biologisk nedbrydelig polymer og fremgangsmåde til fremstilling af samme
US6455526B1 (en) * 1998-12-16 2002-09-24 Aventis Pharmaceuticals, Inc. Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same
GB9828861D0 (en) 1998-12-31 1999-02-17 Danbiosyst Uk Compositions
DE60030828T2 (de) 1999-07-09 2007-02-08 Bts Holding International Bv Optische abtastvorrichtung mit umschaltbarer auflösung
CA2405205C (en) 2000-04-28 2007-11-20 Tanabe Seiyaku Co., Ltd. Method for preparing microspheres
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
DE10055742B4 (de) * 2000-11-10 2006-05-11 Schwarz Pharma Ag Neue Polyester, Verfahren zu ihrer Herstellung und aus den Polyestern hergestellte Depot-Arzneiformen
WO2002087586A1 (en) * 2001-04-26 2002-11-07 Control Delivery Systems, Inc. Sustained release drug delivery system containing codrugs
CN1735404A (zh) * 2002-11-18 2006-02-15 波利梅里斯公司 使用新聚合物的医疗装置
SI1610791T1 (sl) * 2003-03-31 2011-05-31 Titan Pharmaceuticals Inc Implantibilna polimerna naprava za zadržano sproščanje dopaminskega agonista
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen

Also Published As

Publication number Publication date
AU2005287743A1 (en) 2006-03-30
KR20070059161A (ko) 2007-06-11
EP1797871A4 (en) 2012-11-28
JP5081622B2 (ja) 2012-11-28
CA2581143C (en) 2015-03-31
HK1107012A1 (en) 2008-03-28
PL1797871T3 (pl) 2015-07-31
US20080260846A1 (en) 2008-10-23
US8691277B2 (en) 2014-04-08
US9220782B2 (en) 2015-12-29
JP2008513524A (ja) 2008-05-01
US20140255488A1 (en) 2014-09-11
EP1797871A1 (en) 2007-06-20
EP1797871B1 (en) 2015-02-25
AU2005287743B2 (en) 2011-09-29
WO2006032202A1 (fr) 2006-03-30
CA2581143A1 (en) 2006-03-30

Similar Documents

Publication Publication Date Title
ES2536460T3 (es) Formulación de acción prolongada y liberación controlada que contiene un agonista de receptores de dopamina y método de preparación de la misma
CN101534904B (zh) 治疗血小板过量的bcl抑制剂
Tarsy et al. Physostigmine in choreiform movement disorders
US20040180904A1 (en) Novel use of 2h-benzimidazol-2-one, 1,3-Dihydro-1-(2{4-[3-(trifluoromethyl)phenyl]-1-piperazinyl}ethyl)-and its physiologically acceptable addition salts
JP2020517618A (ja) Ｅｈｍｔ２阻害剤との併用療法
BR112012019374A2 (pt) composição farmacêutica, pellet de liberação prolongada, composição farmacêutica oral, método para tratamento de uma doença neurodegenerativa ou um dano ao sistema nervoso em um indivíduo necessitado do mesmo e método para preparação de uma formulação de liberação prolongada de um agente ativo
AR056564A1 (es) Formas de presentacion farmaceuticas solidas de administracion oral con liberacion rapida del principio activo
CL2012000001A1 (es) Compuestos derivados de heteroarilo-pirazolopirimidina-carboxamida, inhibidores de jak; composicion farmaceutica que los comprende; utiles para el tratamiento de la artritis reumatoide, enfermedad de chron, dermatitis, psoriasis, entre otros.
JP2014518266A5 (https=)
EP2762480A1 (en) Oxazolidinone antibiotics containing fused ring
SV2009003288A (es) Derivados de 2, 3-dihidroimidazo [1,2-c] quinazolina sustituidos de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogenesis
UY31676A1 (es) "derivados de 3-metil-imidiazo-[1,2-b]-piridazina"
MX2010009395A (es) Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y procesos para preparacion de los mismos.
TWI667237B (zh) 使用氮雜雙環化合物之癌併用療法
RU2011138962A (ru) Производные 4-изопропилфенилглюцита в качестве ингибиторов sglt1
MX2011008910A (es) Derivados de azol sustituidos, composicion farmaceutica que comprende los derivados, y uso de los derivados para tratar enfermeda de parkinson.
RU2008145714A (ru) Пуриновые производные в качестве активатора аденозинового рецептора
MX2011010732A (es) Pirimidinas sustituidas por imidazol utiles en el tratamiento de trastornos relacionados con glucogeno sintasa cinasa 3 como la enfermedad de alzheimer.
DE602005014341D1 (de) Benzimidazolsubstituierte thiophenderivate, die auf ikk3 wirken
ECSP099382A (es) Sulfonamidas heterocíclicos que tienen actividad antagonista edg-i
RU2013127420A (ru) Способы уменьшения психогенного или компульсивного переедания
MX2010009756A (es) Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y proceso para preparacion de los mismos.
WO2000061126A2 (en) Method of treating neurological disorders with combinations of nitric oxide synthase inhibitors and excitatory amino acid receptor modulators
EP2753322A1 (fr) Schema d'administration du n- hydroxy - 4 - {2- [3- (n, n- dimethylaminomethyl) benzofuran- 2 - ylcarbonylamino]ethoxy} benzamide
JP2014510782A5 (https=)